Medial temporal lobectomy is effective in improving seizure outcomes among patients with drug-resistant temporal lobe epilepsy.

Mike Frazier was living the dream. The 2013 graduate of Frederick County’s Millbrook High School moved to Seattle in 2022 ...

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

At final follow-up, 15 respondents (75%) reached Engel class I (no seizures) and 5 respondents (25%) reached Engel class II (rare, nondisabling seizures). HealthDay News — Medial temporal ...

These cases suggest that good seizure control after a successful ... that have contributed to suicidality. Frontal and temporal lobe networks and changes in serotonergic activity have been ...

Apr. 15, 2025 — Certain common genetic changes might make some people with focal epilepsy less responsive to seizure medications, finds a new global ... Could an Arthritis Drug Unlock Lasting ...

The new International League Against Epilepsy (ILAE) definition of epilepsy results in a higher frequency of epilepsy ...

Focal cortical dysplasia (FCD) type 2 is a congenital malformation of the cerebral cortex that is often associated with difficult-to-treat epilepsy. In the affected areas, nerve cells and their layer ...

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~~ Additional regulatory update and guidance on the Biologics ...

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics ...